The Flow Cytometry and Cellular Imaging Core Facility (FCCICF) provides cellular analysis to investigators with peer-reviewed grants. The FCCICF has two sites, on the north campus and on the recently-opened south campus. It occupies 1900 sq. ft. and is directed by Dr. Michael Andreeff. The FCCICF develops and provides techniques for single-cell analysis. Cell phenotyping, proliferation, signaling and apoptosis assays have been established and modified for multiparametric analysis. Immunophenotypic analysis was combined with assays of intracellular proteins related to apoptosis (Bcl-2, Bcl-XL, BAG-1, p53, Rb, caspase activation, mitochondria! membrane potential and Fas), cell signaling (MARK), proliferation (Ki67, cyclins, BrDU, PCNA, DNA) and cell division history (CFSE). Quantitation of cellular antigens allows determination of the antibodybinding capacity per cell. Rare events and progenitor/stem cell subpopulations can be detected and isolated by three-laser excitation/eight-parameter fluorescence-activated cell sorting (FACS) for subsequent analysis by molecular cytogenetic and other molecular techniques including quantitation of intracellular PKCoc, Bax, Bcl-2, ERK, pERK, XIAP by laser scanning cytometry. FISH has been combined with apoptosis assays to discriminate apoptosis in normal and malignant cells. The number, phenotype and proliferation of minimal residual disease cells can be determined at levels of one malignant in 30,000 normal cells. Methods for detection of transgene expression in cells are in place using p-galactosidase (p-gal), nerve growth factor receptor (NGF-R), and green fluorescent protein (EGFP). Acquisition of 3 new FACS Aria cell sorters and a four-laser flow cytometer (B&D LSRII) has upgraded the facility to provide state-of-the-art isolation and analysis. Laser confocal microscopy has been used extensively and was upgraded by acquisition of an Olympus FV-500 multi-user instrument and a DSU spinning disc confocal system. High-impact studies in cancer prevention, growth factor signaling in breast cancer, apoptosis regulation in leukemias and multistep tumorigenesis all utilized confocal microscopy. The FCCICF now utilizes 17 major instrument systems. The Core supports numerous R01, P01, R21, and SPORE grants. Since the previous review, the number of users has increased 145% (169 investigators with peer-reviewed grants from 19 different programs). 67% of users have peer-reviewed funding. During the previous funding period, 11,668 hours of service was provided. Use has tripled to greater than 7,000 hours estimated for 2007. Future plans are focused on the continued development and application of cutting-edge technologies in cell analysis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-34
Application #
7928901
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-07-01
Budget End
2010-06-30
Support Year
34
Fiscal Year
2009
Total Cost
$566,884
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Taylor, Alison M; Shih, Juliann; Ha, Gavin et al. (2018) Genomic and Functional Approaches to Understanding Cancer Aneuploidy. Cancer Cell 33:676-689.e3
Golemis, Erica A; Scheet, Paul; Beck, Tim N et al. (2018) Molecular mechanisms of the preventable causes of cancer in the United States. Genes Dev 32:868-902
Jabbour, Elias; DerSarkissian, Maral; Duh, Mei Sheng et al. (2018) Efficacy of Ponatinib Versus Earlier Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 18:257-265
Pataer, Apar; Shao, Ruping; Correa, Arlene M et al. (2018) Major pathologic response and RAD51 predict survival in lung cancer patients receiving neoadjuvant chemotherapy. Cancer Med 7:2405-2414
Short, Nicholas J; Kantarjian, Hagop; Ravandi, Farhad et al. (2018) A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma 59:813-820
Shank, Brandon R; Deaver, Melissa; Baker, Angela et al. (2018) Interdisciplinary implementation of tacrolimus intravenous standard concentration in hematopoietic stem cell transplantation recipients. J Oncol Pharm Pract 24:365-370
Keung, Emily Z; Chiang, Yi-Ju; Voss, Rachel K et al. (2018) Defining the incidence and clinical significance of lymph node metastasis in soft tissue sarcoma. Eur J Surg Oncol 44:170-177
Wang, Jue; Zhao, Wei; Guo, Huifang et al. (2018) AKT isoform-specific expression and activation across cancer lineages. BMC Cancer 18:742
Lu, Zhongming; Sturgis, Erich M; Zhu, Lijun et al. (2018) Mouse double minute 4 variants modify susceptibility to risk of recurrence in patients with squamous cell carcinoma of the oropharynx. Mol Carcinog 57:361-369
Murray, Thomas A; Yuan, Ying; Thall, Peter F et al. (2018) A utility-based design for randomized comparative trials with ordinal outcomes and prognostic subgroups. Biometrics 74:1095-1103

Showing the most recent 10 out of 12418 publications